Helena Yu

Ning Zhao & Ge Li Endowed Chair · New York Presbyterian Hospital

Credentials: · · · ·

History

Drivers of Histologic Transformation in EGFR-Mutant Lung Cancer
National Cancer Institute · R01
Contact PI · $2M · Sloan-Kettering Inst Can Research
2021–2027

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Principal investigator · Recruiting · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2026–2028
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2021–2025
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2020–2027
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2019–2025